Abstract
18. Secondary endpoints (PATH extension study): Long-term outcomes of subcutaneous immunoglobulin IgPro20 in CIDP maintenance treatment
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have